GDS Wealth Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-2,030
Closed -$242K 177
2024
Q3
$242K Buy
2,030
+2
+0.1% +$267 0.02% 154
2024
Q2
$289K Buy
2,028
+9
+0.4% +$1.19K 0.03% 113
2024
Q1
$259K Buy
+2,019
New +$240K 0.03% 119
2023
Q4
Sell
-2,352
Closed -$214K 134
2023
Q3
$214K Buy
+2,352
New +$207K 0.03% 116

Other funds holding NVO

GDS Wealth Management's NVO Position: Q4 2024 in Review

GDS Wealth Management sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 2,030 shares — an estimated $242K sold.

GDS Wealth Management first reported a position in NVO in Q3 2023 and held it in 4 quarters. The position peaked at $289K in Q2 2024. 1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

  • GDS Wealth Management reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
  • GDS Wealth Management sold 2,030 Novo Nordisk shares in Q4 2024, an estimated $242K.
  • GDS Wealth Management first reported a position in Novo Nordisk in Q3 2023 and held it in 4 quarters.
  • GDS Wealth Management's Novo Nordisk position peaked at $289K in Q2 2024.
  • 1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on GDS Wealth Management's 13F filing for Q4 2024, filed 24 Jan 2025.